Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Kumar, Shaji [VerfasserIn]   i
 Goldschmidt, Hartmut [VerfasserIn]   i
 Hillengaß, Jens [VerfasserIn]   i
Titel:Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors
Titelzusatz:a multicenter IMWG study
Verf.angabe:S.K. Kumar, M. A. Dimopoulos, E. Kastritis, E. Terpos, H. Nahi, H. Goldschmidt, J. Hillengass, X. Leleu, M. Beksac, M. Alsina, A. Oriol, M. Cavo, E.M. Ocio, M.V. Mateos, E.K. O'Donnell, R. Vij, H.M. Lokhorst, N.W.C.J. van de Donk, C. Min, T. Mark, I. Turesson, M. Hansson, H. Ludwig, S. Jagannath, M. Delforge, C. Kyriakou, P. Hari, U. Mellqvist, S.Z. Usmani, D. Dytfeld, A.Z. Badros, P. Moreau, K. Kim, P.R. Otero, J.H. Lee, C. Shustik, D. Waller, W.J. Chng, S. Ozaki, J.-J. Lee, J. de la Rubia, H.S. Eom, L. Rosinol, J.J. Lahuerta, A. Sureda, J.S. Kim and B.G.M. Durie
E-Jahr:2017
Jahr:November 2017
Umfang:6 S.
Fussnoten:Gesehen am 07.11.2018
Titel Quelle:Enthalten in: Leukemia
Ort Quelle:London : Springer Nature, 1997
Jahr Quelle:2017
Band/Heft Quelle:31(2017), 11, Seite 2443-2448
ISSN Quelle:1476-5551
Abstract:Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have received at least three prior lines of therapy, are refractory to both an IMiD (lenalidomide or pomalidomide) and a PI (bortezomib or carfilzomib), and have been exposed to an alkylating agent were identified. The time patients met the above criteria was defined as time zero (T0). Five hundred and forty-three patients diagnosed between 2006 and 2014 were enrolled in this study. Median age at T0 was 62 years (range 31-87); 61% were males. The median duration between diagnosis and T0 was 3.1 years. The median number of lines of therapy before T0 was 4 (range 3-13). The median overall survival (OS) from T0 for the entire cohort was 13 (95% confidence interval (CI) 11, 15) months. At least one regimen recorded after T0 in 462 (85%) patients, with a median (95% CI) progression-free survival and OS from T0 of 5 (4, 6), and 15.2 (13, 17) months, respectively. The study provides the expected outcome of relapsed multiple myeloma that is refractory to a PI and an IMiD, a benchmark for comparison of new therapies being evaluated.
DOI:doi:10.1038/leu.2017.138
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: http://dx.doi.org/10.1038/leu.2017.138
 Volltext: https://www.nature.com/articles/leu2017138
 DOI: https://doi.org/10.1038/leu.2017.138
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1582670579
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68325862   QR-Code
zum Seitenanfang